Hmdb loader
Survey

Showing metabocard for Hypoxanthine (HMDB0000157)

Jump To Section:
IdentificationTaxonomyOntologyPhysical propertiesSpectraBiological propertiesConcentrationsLinksReferencesenzymes (4) Show 4 proteinsXML
enzymes (4) Show 4 proteins
Record Information
Version5.0
StatusDetected and Quantified
Creation Date2005-11-16 15:48:42 UTC
Update Date2023-05-30 20:55:56 UTC
HMDB IDHMDB0000157
Secondary Accession Numbers
  • HMDB00157
Metabolite Identification
Common NameHypoxanthine
DescriptionHypoxanthine, also known as purine-6-ol or Hyp, belongs to the class of organic compounds known as purines. Purines are a bicyclic aromatic compound made up of a pyrimidine ring fused to an imidazole ring. Hypoxanthine is also classified as an oxopurine, Hypoxanthine is a naturally occurring purine derivative and a reaction intermediate in the metabolism of adenosine and in the formation of nucleic acids by the nucleotide salvage pathway. Hypoxanthine exists in all living species, ranging from bacteria to plants to humans. Hypoxanthine has been detected, but not quantified in, several different foods, such as radish (var.), mountain yams, welsh onions, greenthread tea, and common beets. Hypoxanthine is occasionally found as a constituent of nucleic acids, where it is present in the anticodon of tRNA in the form of its nucleoside inosine. Biologically, hypoxanthine can be formed a number of ways. For instance, it is one of the products of the action of xanthine oxidase on xanthine. However, more frequently xanthine is formed from oxidation of hypoxanthine by xanthine oxidoreductase. The enzyme hypoxanthine-guanine phosphoribosyltransferase converts hypoxanthine into IMP in the nucleotide salvage pathway. Hypoxanthine is also a spontaneous deamination product of adenine. Under normal circumstances hypoxanthine is readily converted to uric acid. In this process, hypoxanthine is first oxidized to xanthine, which is further oxidized to uric acid by xanthine oxidase. Molecular oxygen, the oxidant in both reactions, is reduced to H2O2 and other reactive oxygen species. In humans, uric acid is the final product of purine degradation and is excreted in the urine. Within humans, hypoxanthine participates in a number of other enzymatic reactions. In particular, hypoxanthine and ribose 1-phosphate can be biosynthesized from inosine through its interaction with the enzyme purine nucleoside phosphorylase. Hypoxanthine is also involved in the metabolic disorder called the purine nucleoside phosphorylase deficiency. Purine nucleoside phosphorylase (PNP) deficiency is a disorder of the immune system (primary immunodeficiency) characterized by recurrent infections, neurologic symptoms, and autoimmune disorders. PNP deficiency causes a shortage of white blood cells, called T-cells, that help fight infection. Affected individuals develop neurologic symptoms, such as stiff or rigid muscles (spasticity), uncoordinated movements (ataxia), developmental delay, and intellectual disability. PNP deficiency is associated with an increased risk to develop autoimmune disorders, such as autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura (ITP), autoimmune neutropenia, thyroiditis, and lupus.
Structure
Data?1676999674
MOL3D MOLSDF3D SDFPDB3D PDBSMILESInChI

MOL for HMDB0000157 (Hypoxanthine)

Hypoxanthine.mol
  Mrv1652309032023542D          

 10 11  0  0  0  0            999 V2000
    0.8643    0.2549    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.3492   -0.4125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8643   -1.0799    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0797   -0.8250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6348   -1.2375    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3492   -0.8250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3492    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6348    0.4125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6348    1.2375    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0797    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0  0  0  0
  2  3  2  0  0  0  0
  3  4  1  0  0  0  0
  4  5  1  0  0  0  0
  5  6  2  0  0  0  0
  6  7  1  0  0  0  0
  7  8  2  0  0  0  0
  8  9  1  0  0  0  0
  8 10  1  0  0  0  0
  1 10  1  0  0  0  0
  4 10  2  0  0  0  0
M  END
Download

3D MOL for HMDB0000157 (Hypoxanthine)

HMDB0000157
     RDKit          3D
Hypoxanthine
 14 15  0  0  0  0  0  0  0  0999 V2000
    0.9522    2.2049   -0.4111 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.9951    0.8403   -0.1712 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1426    0.1543   -0.0098 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.1416   -1.1774    0.2228 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9580   -1.7939    0.2876 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2266   -1.1687    0.1354 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5168   -1.5621    0.1574 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3107   -0.4972   -0.0574 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5008    0.5652   -0.2136 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2222    0.1859   -0.1010 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6791    2.8534    0.3125 H   0  0  0  0  0  0  0  0  0  0  0  0
    3.0880   -1.6921    0.3470 H   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4100   -0.4808   -0.1001 H   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7694    1.5682   -0.3985 H   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  1  0
 10  2  1  0
 10  6  2  0
  1 11  1  0
  4 12  1  0
  8 13  1  0
  9 14  1  0
M  END
Download

3D SDF for HMDB0000157 (Hypoxanthine)

Hypoxanthine.mol
  Mrv1652309032023542D          

 10 11  0  0  0  0            999 V2000
    0.8643    0.2549    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.3492   -0.4125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8643   -1.0799    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0797   -0.8250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6348   -1.2375    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3492   -0.8250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3492    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6348    0.4125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6348    1.2375    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0797    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0  0  0  0
  2  3  2  0  0  0  0
  3  4  1  0  0  0  0
  4  5  1  0  0  0  0
  5  6  2  0  0  0  0
  6  7  1  0  0  0  0
  7  8  2  0  0  0  0
  8  9  1  0  0  0  0
  8 10  1  0  0  0  0
  1 10  1  0  0  0  0
  4 10  2  0  0  0  0
M  END
> <DATABASE_ID>
HMDB0000157

> <DATABASE_NAME>
hmdb

> <SMILES>
OC1=NC=NC2=C1NC=N2

> <INCHI_IDENTIFIER>
InChI=1S/C5H4N4O/c10-5-3-4(7-1-6-3)8-2-9-5/h1-2H,(H2,6,7,8,9,10)

> <INCHI_KEY>
FDGQSTZJBFJUBT-UHFFFAOYSA-N

> <FORMULA>
C5H4N4O

> <MOLECULAR_WEIGHT>
136.1115

> <EXACT_MASS>
136.03851077

> <JCHEM_ACCEPTOR_COUNT>
4

> <JCHEM_ATOM_COUNT>
14

> <JCHEM_AVERAGE_POLARIZABILITY>
11.817749402233233

> <JCHEM_BIOAVAILABILITY>
1

> <JCHEM_DONOR_COUNT>
2

> <JCHEM_FORMAL_CHARGE>
0

> <JCHEM_GHOSE_FILTER>
0

> <JCHEM_IUPAC>
7H-purin-6-ol

> <ALOGPS_LOGP>
-0.55

> <JCHEM_LOGP>
-0.048109598333333205

> <ALOGPS_LOGS>
-1.02

> <JCHEM_MDDR_LIKE_RULE>
0

> <JCHEM_NUMBER_OF_RINGS>
2

> <JCHEM_PHYSIOLOGICAL_CHARGE>
0

> <JCHEM_PKA>
14.243772630076094

> <JCHEM_PKA_STRONGEST_ACIDIC>
8.715984164481101

> <JCHEM_PKA_STRONGEST_BASIC>
1.7329101446499238

> <JCHEM_POLAR_SURFACE_AREA>
74.69

> <JCHEM_REFRACTIVITY>
35.49999999999999

> <JCHEM_ROTATABLE_BOND_COUNT>
0

> <JCHEM_RULE_OF_FIVE>
1

> <ALOGPS_SOLUBILITY>
1.30e+01 g/l

> <JCHEM_TRADITIONAL_IUPAC>
6-hydroxypurine

> <JCHEM_VEBER_RULE>
0

$$$$
Download

3D-SDF for HMDB0000157 (Hypoxanthine)

HMDB0000157
     RDKit          3D
Hypoxanthine
 14 15  0  0  0  0  0  0  0  0999 V2000
    0.9522    2.2049   -0.4111 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.9951    0.8403   -0.1712 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1426    0.1543   -0.0098 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.1416   -1.1774    0.2228 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9580   -1.7939    0.2876 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2266   -1.1687    0.1354 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5168   -1.5621    0.1574 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3107   -0.4972   -0.0574 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5008    0.5652   -0.2136 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2222    0.1859   -0.1010 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6791    2.8534    0.3125 H   0  0  0  0  0  0  0  0  0  0  0  0
    3.0880   -1.6921    0.3470 H   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4100   -0.4808   -0.1001 H   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7694    1.5682   -0.3985 H   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  1  0
 10  2  1  0
 10  6  2  0
  1 11  1  0
  4 12  1  0
  8 13  1  0
  9 14  1  0
M  END
Download

PDB for HMDB0000157 (Hypoxanthine)

HEADER    PROTEIN                                 03-SEP-20   NONE
TITLE     NULL                                                        
COMPND    MOLECULE: Hypoxanthine.mol                                  
SOURCE    NULL                                                        
KEYWDS    NULL                                                        
EXPDTA    NULL                                                        
AUTHOR    Marvin                                                      
REVDAT   1   03-SEP-20         0                                  
HETATM    1  N   UNK     0       1.613   0.476   0.000  0.00  0.00           N+0
HETATM    2  C   UNK     0       2.519  -0.770   0.000  0.00  0.00           C+0
HETATM    3  N   UNK     0       1.613  -2.016   0.000  0.00  0.00           N+0
HETATM    4  C   UNK     0       0.149  -1.540   0.000  0.00  0.00           C+0
HETATM    5  N   UNK     0      -1.185  -2.310   0.000  0.00  0.00           N+0
HETATM    6  C   UNK     0      -2.519  -1.540   0.000  0.00  0.00           C+0
HETATM    7  N   UNK     0      -2.519   0.000   0.000  0.00  0.00           N+0
HETATM    8  C   UNK     0      -1.185   0.770   0.000  0.00  0.00           C+0
HETATM    9  O   UNK     0      -1.185   2.310   0.000  0.00  0.00           O+0
HETATM   10  C   UNK     0       0.149   0.000   0.000  0.00  0.00           C+0
CONECT    1    2   10                                                       
CONECT    2    1    3                                                       
CONECT    3    2    4                                                       
CONECT    4    3    5   10                                                  
CONECT    5    4    6                                                       
CONECT    6    5    7                                                       
CONECT    7    6    8                                                       
CONECT    8    7    9   10                                                  
CONECT    9    8                                                            
CONECT   10    8    1    4                                                  
MASTER        0    0    0    0    0    0    0    0   10    0   22    0
END
Download

3D PDB for HMDB0000157 (Hypoxanthine)

COMPND    HMDB0000157
HETATM    1  O1  UNL     1       0.952   2.205  -0.411  1.00  0.00           O  
HETATM    2  C1  UNL     1       0.995   0.840  -0.171  1.00  0.00           C  
HETATM    3  N1  UNL     1       2.143   0.154  -0.010  1.00  0.00           N  
HETATM    4  C2  UNL     1       2.142  -1.177   0.223  1.00  0.00           C  
HETATM    5  N2  UNL     1       0.958  -1.794   0.288  1.00  0.00           N  
HETATM    6  C3  UNL     1      -0.227  -1.169   0.135  1.00  0.00           C  
HETATM    7  N3  UNL     1      -1.517  -1.562   0.157  1.00  0.00           N  
HETATM    8  C4  UNL     1      -2.311  -0.497  -0.057  1.00  0.00           C  
HETATM    9  N4  UNL     1      -1.501   0.565  -0.214  1.00  0.00           N  
HETATM   10  C5  UNL     1      -0.222   0.186  -0.101  1.00  0.00           C  
HETATM   11  H1  UNL     1       0.679   2.853   0.312  1.00  0.00           H  
HETATM   12  H2  UNL     1       3.088  -1.692   0.347  1.00  0.00           H  
HETATM   13  H3  UNL     1      -3.410  -0.481  -0.100  1.00  0.00           H  
HETATM   14  H4  UNL     1      -1.769   1.568  -0.398  1.00  0.00           H  
CONECT    1    2   11
CONECT    2    3    3   10
CONECT    3    4
CONECT    4    5    5   12
CONECT    5    6
CONECT    6    7   10   10
CONECT    7    8    8
CONECT    8    9   13
CONECT    9   10   14
END
Download

SMILES for HMDB0000157 (Hypoxanthine)

OC1=NC=NC2=C1NC=N2
Download

INCHI for HMDB0000157 (Hypoxanthine)

InChI=1S/C5H4N4O/c10-5-3-4(7-1-6-3)8-2-9-5/h1-2H,(H2,6,7,8,9,10)
Download
View in JSmolView NMR AssignmentsView Stereo Labels
Synonyms
ValueSource
6(1H)-PurinoneChEBI
6-OxopurineChEBI
9H-Purin-6(1H)-oneChEBI
HypChEBI
Purin-6(1H)-oneChEBI
Purine-6-olChEBI
1,7-Dihydro-6H-purin-6-oneHMDB
1,7-Dihydro-6H-purine-6-oneHMDB
1H,7H-HypoxanthineHMDB
3H-Purin-6-olHMDB
4-Hydroxy-1H-purineHMDB
6-Hydroxy-1H-purineHMDB
6-HydroxypurineHMDB
7H-Purin-6-olHMDB
9H-Purin-6-olHMDB
Hypoxanthine enolHMDB
Purin-6(3H)-oneHMDB
Purin-6-olHMDB
SarcineHMDB
SarkinHMDB
SarkineHMDB
Chemical FormulaC5H4N4O
Average Molecular Weight136.1115
Monoisotopic Molecular Weight136.03851077
IUPAC Name7H-purin-6-ol
Traditional Name6-hydroxypurine
CAS Registry Number68-94-0
SMILES
OC1=NC=NC2=C1NC=N2
InChI Identifier
InChI=1S/C5H4N4O/c10-5-3-4(7-1-6-3)8-2-9-5/h1-2H,(H2,6,7,8,9,10)
InChI KeyFDGQSTZJBFJUBT-UHFFFAOYSA-N
Chemical Taxonomy
Description Belongs to the class of organic compounds known as hypoxanthines. Hypoxanthines are compounds containing the purine derivative 1H-purin-6(9H)-one. Purine is a bicyclic aromatic compound made up of a pyrimidine ring fused to an imidazole ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassImidazopyrimidines
Sub ClassPurines and purine derivatives
Direct ParentHypoxanthines
Alternative Parents
Substituents
  • 6-oxopurine
  • Hypoxanthine
  • Pyrimidone
  • Pyrimidine
  • Azole
  • Imidazole
  • Vinylogous amide
  • Heteroaromatic compound
  • Azacycle
  • Organic oxide
  • Organopnictogen compound
  • Organooxygen compound
  • Organonitrogen compound
  • Organic nitrogen compound
  • Organic oxygen compound
  • Hydrocarbon derivative
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Ontology
Physiological effect
Health effect
Disposition
Biological locationRoute of exposureSource
Process
Naturally occurring process
Role
Industrial applicationBiological role
Physical Properties
StateSolid
Experimental Molecular Properties
PropertyValueReference
Melting Point150 °CNot Available
Boiling PointNot AvailableNot Available
Water Solubility0.7 mg/mLYALKOWSKY,SH & DANNENFELSER,RM (1992)
LogP-1.11HANSCH,C ET AL. (1995)
Experimental Chromatographic Properties

Experimental Collision Cross Sections

Adduct TypeData SourceCCS Value (Å2)Reference
[M-H]-Astarita_neg118.330932474
[M-H]-Baker126.37630932474
[M+H]+Astarita_pos120.330932474
[M+H]+Baker135.79330932474
[M+H]+MetCCS_test_pos127.05630932474
[M-H]-Not Available120.6http://allccs.zhulab.cn/database/detail?ID=AllCCS00000479
[M+H]+Not Available129.3http://allccs.zhulab.cn/database/detail?ID=AllCCS00000479
Predicted Molecular Properties
PropertyValueSource
Water Solubility13 g/LALOGPS
logP-0.55ALOGPS
logP-0.048ChemAxon
logS-1ALOGPS
pKa (Strongest Acidic)8.72ChemAxon
pKa (Strongest Basic)1.73ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area74.69 ŲChemAxon
Rotatable Bond Count0ChemAxon
Refractivity35.5 m³·mol⁻¹ChemAxon
Polarizability11.82 ųChemAxon
Number of Rings2ChemAxon
BioavailabilityYesChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted Chromatographic Properties

Predicted Collision Cross Sections

PredictorAdduct TypeCCS Value (Å2)Reference
DarkChem[M+H]+125.1531661259
DarkChem[M-H]-123.37531661259
AllCCS[M+H]+128.59632859911
AllCCS[M-H]-121.46232859911
DeepCCS[M+H]+124.53830932474
DeepCCS[M-H]-122.39630932474
DeepCCS[M-2H]-158.50530932474
DeepCCS[M+Na]+133.26230932474
AllCCS[M+H]+128.632859911
AllCCS[M+H-H2O]+123.832859911
AllCCS[M+NH4]+133.132859911
AllCCS[M+Na]+134.432859911
AllCCS[M-H]-121.532859911
AllCCS[M+Na-2H]-122.732859911
AllCCS[M+HCOO]-124.032859911

Predicted Kovats Retention Indices

Underivatized

MetaboliteSMILESKovats RI ValueColumn TypeReference
HypoxanthineOC1=NC=NC2=C1NC=N22188.8Standard polar33892256
HypoxanthineOC1=NC=NC2=C1NC=N21838.4Standard non polar33892256
HypoxanthineOC1=NC=NC2=C1NC=N21644.4Semi standard non polar33892256

Derivatized

Derivative Name / StructureSMILESKovats RI ValueColumn TypeReference
Hypoxanthine,1TMS,isomer #1C[Si](C)(C)OC1=NC=NC2=C1[NH]C=N21725.0Semi standard non polar33892256
Hypoxanthine,1TMS,isomer #2C[Si](C)(C)N1C=NC2=NC=NC(O)=C211814.0Semi standard non polar33892256
Hypoxanthine,2TMS,isomer #1C[Si](C)(C)OC1=NC=NC2=C1N([Si](C)(C)C)C=N21820.6Semi standard non polar33892256
Hypoxanthine,2TMS,isomer #1C[Si](C)(C)OC1=NC=NC2=C1N([Si](C)(C)C)C=N21750.3Standard non polar33892256
Hypoxanthine,2TMS,isomer #1C[Si](C)(C)OC1=NC=NC2=C1N([Si](C)(C)C)C=N22268.6Standard polar33892256
Hypoxanthine,1TBDMS,isomer #1CC(C)(C)[Si](C)(C)OC1=NC=NC2=C1[NH]C=N21957.5Semi standard non polar33892256
Hypoxanthine,1TBDMS,isomer #2CC(C)(C)[Si](C)(C)N1C=NC2=NC=NC(O)=C212064.3Semi standard non polar33892256
Hypoxanthine,2TBDMS,isomer #1CC(C)(C)[Si](C)(C)OC1=NC=NC2=C1N([Si](C)(C)C(C)(C)C)C=N22231.5Semi standard non polar33892256
Hypoxanthine,2TBDMS,isomer #1CC(C)(C)[Si](C)(C)OC1=NC=NC2=C1N([Si](C)(C)C(C)(C)C)C=N22172.7Standard non polar33892256
Hypoxanthine,2TBDMS,isomer #1CC(C)(C)[Si](C)(C)OC1=NC=NC2=C1N([Si](C)(C)C(C)(C)C)C=N22420.5Standard polar33892256
Spectra

GC-MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Experimental GC-MSGC-MS Spectrum - Hypoxanthine GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (2 TMS)splash10-0159-3970000000-0d844fae4a1ffe1588232014-06-16HMDB team, MONA, MassBankView Spectrum
Experimental GC-MSGC-MS Spectrum - Hypoxanthine GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (Non-derivatized)splash10-014i-1790000000-ae93bf8bf07b30b65e1a2014-06-16HMDB team, MONA, MassBankView Spectrum
Experimental GC-MSGC-MS Spectrum - Hypoxanthine GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (2 TMS)splash10-00di-9340000000-1184c503fb61344c48532014-06-16HMDB team, MONA, MassBankView Spectrum
Experimental GC-MSGC-MS Spectrum - Hypoxanthine GC-MS (2 TMS)splash10-014i-3590000000-a419976950afe7934cbc2014-06-16HMDB team, MONA, MassBankView Spectrum
Experimental GC-MSGC-MS Spectrum - Hypoxanthine EI-B (Non-derivatized)splash10-000i-9800000000-9c266d6963658e9d2cf12017-09-12HMDB team, MONA, MassBankView Spectrum
Experimental GC-MSGC-MS Spectrum - Hypoxanthine GC-EI-TOF (Non-derivatized)splash10-0159-3970000000-0d844fae4a1ffe1588232017-09-12HMDB team, MONA, MassBankView Spectrum
Experimental GC-MSGC-MS Spectrum - Hypoxanthine GC-EI-TOF (Non-derivatized)splash10-014i-1790000000-ae93bf8bf07b30b65e1a2017-09-12HMDB team, MONA, MassBankView Spectrum
Experimental GC-MSGC-MS Spectrum - Hypoxanthine GC-EI-TOF (Non-derivatized)splash10-00di-9340000000-1184c503fb61344c48532017-09-12HMDB team, MONA, MassBankView Spectrum
Experimental GC-MSGC-MS Spectrum - Hypoxanthine GC-MS (Non-derivatized)splash10-014i-3590000000-a419976950afe7934cbc2017-09-12HMDB team, MONA, MassBankView Spectrum
Experimental GC-MSGC-MS Spectrum - Hypoxanthine GC-EI-TOF (Non-derivatized)splash10-014i-2890000000-3be4d08be45781881bc12017-09-12HMDB team, MONA, MassBankView Spectrum
Experimental GC-MSGC-MS Spectrum - Hypoxanthine GC-EI-TOF (Non-derivatized)splash10-014i-1590000000-bb6f003bfa7bd04628a12017-09-12HMDB team, MONA, MassBankView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Hypoxanthine GC-MS (Non-derivatized) - 70eV, Positivesplash10-0a5i-8900000000-e20eb5d939a2c406a6e22016-09-22Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Hypoxanthine GC-MS (1 TMS) - 70eV, Positivesplash10-0613-5900000000-be0624b928ba71cc797d2017-10-06Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Hypoxanthine GC-MS (Non-derivatized) - 70eV, PositiveNot Available2021-10-12Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Hypoxanthine GC-MS (TMS_1_2) - 70eV, PositiveNot Available2021-11-05Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Hypoxanthine GC-MS (TBDMS_1_1) - 70eV, PositiveNot Available2021-11-05Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Hypoxanthine GC-MS (TBDMS_1_2) - 70eV, PositiveNot Available2021-11-05Wishart LabView Spectrum
MSMass Spectrum (Electron Ionization)splash10-000i-8900000000-ebf57ea530a2d4e31ffa2014-09-20Not AvailableView Spectrum

MS/MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Experimental LC-MS/MSLC-MS/MS Spectrum - Hypoxanthine Quattro_QQQ 10V, Positive-QTOF (Annotated)splash10-000i-0900000000-2b36c20acd9973b317f52012-07-24HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Hypoxanthine Quattro_QQQ 25V, Positive-QTOF (Annotated)splash10-0api-9800000000-fb4e3cccb7d27d119feb2012-07-24HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Hypoxanthine Quattro_QQQ 40V, Positive-QTOF (Annotated)splash10-0aor-9200000000-33c2f9eedf9a878530be2012-07-24HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Hypoxanthine EI-B (HITACHI M-80) , Positive-QTOFsplash10-000i-9800000000-9c266d6963658e9d2cf12012-08-31HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Hypoxanthine LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Positive-QTOFsplash10-000i-0910000000-4da64abddc3ac8ab573a2012-08-31HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Hypoxanthine LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Positive-QTOFsplash10-014i-1900000000-859f61101b12be0b29782012-08-31HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Hypoxanthine LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Positive-QTOFsplash10-014i-1900000000-f5d899e7988568d5bcab2012-08-31HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Hypoxanthine LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Positive-QTOFsplash10-000i-0900000000-e19e6d04568d3560eb4a2012-08-31HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Hypoxanthine LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Positive-QTOFsplash10-000i-0910000000-8def0d2ec821528267632012-08-31HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Hypoxanthine LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Positive-QTOFsplash10-014i-2900000000-a8361951a2f702a217c72012-08-31HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Hypoxanthine LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Positive-QTOFsplash10-000i-0900000000-3f653a7c81b328e46cb52012-08-31HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Hypoxanthine LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Positive-QTOFsplash10-014i-0080290000-be98ce43421dbf9007fa2012-08-31HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Hypoxanthine LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Negative-QTOFsplash10-000i-0930030000-56ea204dcb077bc174c22012-08-31HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Hypoxanthine LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Negative-QTOFsplash10-0006-9000000000-4c2d1980f9e5e4b720a52012-08-31HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Hypoxanthine LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Negative-QTOFsplash10-000i-0900000000-26b3c93bc9dea5a880322012-08-31HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Hypoxanthine LC-ESI-QQ (API3000, Applied Biosystems) 10V, Negative-QTOFsplash10-000i-1900000000-c367cd4c23aea0f74ecb2012-08-31HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Hypoxanthine LC-ESI-QQ (API3000, Applied Biosystems) 20V, Negative-QTOFsplash10-000l-8900000000-91e35cdcc11d357119f02012-08-31HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Hypoxanthine LC-ESI-QQ (API3000, Applied Biosystems) 30V, Negative-QTOFsplash10-0006-9100000000-4fb8f4ee2d35aa8746172012-08-31HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Hypoxanthine LC-ESI-QQ (API3000, Applied Biosystems) 40V, Negative-QTOFsplash10-014l-9000000000-7934b3037f39d69fc40a2012-08-31HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Hypoxanthine LC-ESI-QQ (API3000, Applied Biosystems) 50V, Negative-QTOFsplash10-014i-9000000000-ad93e267446292bf247b2012-08-31HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Hypoxanthine LC-ESI-QQ (API3000, Applied Biosystems) 10V, Positive-QTOFsplash10-014i-9000000000-4b8f9e13ed7adf0888c22012-08-31HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Hypoxanthine LC-ESI-QQ (API3000, Applied Biosystems) 20V, Positive-QTOFsplash10-014i-9000000000-f295755f591e27bb9f072012-08-31HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Hypoxanthine LC-ESI-QQ (API3000, Applied Biosystems) 30V, Positive-QTOFsplash10-014i-9000000000-aee48a44f42a4b7678442012-08-31HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Hypoxanthine LC-ESI-QQ (API3000, Applied Biosystems) 40V, Positive-QTOFsplash10-014i-9000000000-f5ebd92e86cf00f28cf12012-08-31HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Hypoxanthine LC-ESI-QQ (API3000, Applied Biosystems) 50V, Positive-QTOFsplash10-014i-9000000000-9a1ad1aa2d8fb621b6082012-08-31HMDB team, MONAView Spectrum

NMR Spectra

Spectrum TypeDescriptionDeposition DateSourceView
Experimental 1D NMR1H NMR Spectrum (1D, 600 MHz, H2O, experimental)2012-12-04Wishart LabView Spectrum
Predicted 1D NMR13C NMR Spectrum (1D, 100 MHz, D2O, predicted)2021-09-16Wishart LabView Spectrum
Predicted 1D NMR1H NMR Spectrum (1D, 100 MHz, D2O, predicted)2021-09-16Wishart LabView Spectrum
Predicted 1D NMR13C NMR Spectrum (1D, 200 MHz, D2O, predicted)2021-09-16Wishart LabView Spectrum
Predicted 1D NMR1H NMR Spectrum (1D, 200 MHz, D2O, predicted)2021-09-16Wishart LabView Spectrum
Predicted 1D NMR13C NMR Spectrum (1D, 300 MHz, D2O, predicted)2021-09-16Wishart LabView Spectrum
Predicted 1D NMR1H NMR Spectrum (1D, 300 MHz, D2O, predicted)2021-09-16Wishart LabView Spectrum
Predicted 1D NMR13C NMR Spectrum (1D, 400 MHz, D2O, predicted)2021-09-16Wishart LabView Spectrum
Predicted 1D NMR1H NMR Spectrum (1D, 400 MHz, D2O, predicted)2021-09-16Wishart LabView Spectrum
Predicted 1D NMR13C NMR Spectrum (1D, 500 MHz, D2O, predicted)2021-09-16Wishart LabView Spectrum
Predicted 1D NMR1H NMR Spectrum (1D, 500 MHz, D2O, predicted)2021-09-16Wishart LabView Spectrum
Predicted 1D NMR13C NMR Spectrum (1D, 600 MHz, D2O, predicted)2021-09-16Wishart LabView Spectrum
Predicted 1D NMR1H NMR Spectrum (1D, 600 MHz, D2O, predicted)2021-09-16Wishart LabView Spectrum
Predicted 1D NMR13C NMR Spectrum (1D, 700 MHz, D2O, predicted)2021-09-16Wishart LabView Spectrum
Predicted 1D NMR1H NMR Spectrum (1D, 700 MHz, D2O, predicted)2021-09-16Wishart LabView Spectrum
Predicted 1D NMR13C NMR Spectrum (1D, 800 MHz, D2O, predicted)2021-09-16Wishart LabView Spectrum
Predicted 1D NMR1H NMR Spectrum (1D, 800 MHz, D2O, predicted)2021-09-16Wishart LabView Spectrum
Predicted 1D NMR13C NMR Spectrum (1D, 900 MHz, D2O, predicted)2021-09-16Wishart LabView Spectrum
Predicted 1D NMR1H NMR Spectrum (1D, 900 MHz, D2O, predicted)2021-09-16Wishart LabView Spectrum
Predicted 1D NMR13C NMR Spectrum (1D, 1000 MHz, D2O, predicted)2021-09-16Wishart LabView Spectrum
Predicted 1D NMR1H NMR Spectrum (1D, 1000 MHz, D2O, predicted)2021-09-16Wishart LabView Spectrum
Experimental 2D NMR[1H, 13C]-HSQC NMR Spectrum (2D, 600 MHz, 100%_DMSO, experimental)2012-12-04Wishart LabView Spectrum

IR Spectra

Spectrum TypeDescriptionDeposition DateSourceView
Predicted IR SpectrumIR Ion Spectrum (Predicted IRIS Spectrum, Adduct: [M-H]-)2023-02-03FELIX labView Spectrum
Predicted IR SpectrumIR Ion Spectrum (Predicted IRIS Spectrum, Adduct: [M+H]+)2023-02-03FELIX labView Spectrum
Predicted IR SpectrumIR Ion Spectrum (Predicted IRIS Spectrum, Adduct: [M+Na]+)2023-02-03FELIX labView Spectrum
Biological Properties
Cellular Locations
  • Cytoplasm
  • Extracellular
  • Lysosome
  • Peroxisome
Biospecimen Locations
  • Amniotic Fluid
  • Blood
  • Breast Milk
  • Cellular Cytoplasm
  • Cerebrospinal Fluid (CSF)
  • Feces
  • Saliva
  • Urine
Tissue Locations
  • Adipose Tissue
  • Epidermis
  • Erythrocyte
  • Fibroblasts
  • Intestine
  • Kidney
  • Liver
  • Placenta
  • Platelet
  • Prostate
  • Skeletal Muscle
  • Spleen
  • Testis
Pathways
Normal Concentrations
BiospecimenStatusValueAgeSexConditionReferenceDetails
Amniotic FluidDetected and Quantified0.086 +/- 0.044 uMAdult (>18 years old)FemaleNormal details
BloodDetected and Quantified2.300 +/- 1.100 uMAdult (>18 years old)Not SpecifiedNormal details
BloodDetected but not QuantifiedNot QuantifiedAdult (>18 years old)BothNormal details
BloodDetected and Quantified11.02 +/- 3.67 uMAdult (>18 years old)BothNormal details
BloodDetected and Quantified1.7 +/- 0.4 uMAdult (>18 years old)Male
normal		 details
BloodDetected and Quantified2.2 +/- 1.1 uMAdult (>18 years old)Male
Normal		 details
BloodDetected and Quantified11.0294 +/- 3.676 uMAdult (>18 years old)Both
Normal		 details
BloodDetected and Quantified5.6 (3.1-7.1) uMAdult (>18 years old)FemaleNormal
    • Geigy Scientific ...
 details
BloodDetected and Quantified1.0 +/-0.9 uMAdult (>18 years old)MaleNormal
    • Geigy Scientific ...
 details
BloodDetected and Quantified4.87 +/- 0.36 uMAdult (>18 years old)BothNormal details
BloodDetected and Quantified1.0 +/- 0.9 uMAdult (>18 years old)MaleNormal
    • Geigy Scientific ...
 details
BloodDetected and Quantified5.6 (3.1-7.1) uMAdult (>18 years old)FemaleNormal
    • Geigy Scientific ...
 details
BloodDetected and Quantified0.38 +/- 0.18 uMAdult (>18 years old)MaleNormal details
BloodDetected and Quantified34.2 +/- 10.3 uMAdult (>18 years old)BothNormal details
Breast MilkDetected and Quantified2.3 +/- 1.5 uMAdult (>18 years old)Female
Normal		 details
Cellular CytoplasmDetected and Quantified2 uMAdult (>18 years old)BothNormal details
Cerebrospinal Fluid (CSF)Detected and Quantified5.94 (5.20-6.68) uMAdult (>18 years old)BothNormal details
Cerebrospinal Fluid (CSF)Detected and Quantified2.6+/-0.6 uMChildren (1 - 13 years old)Not SpecifiedNormal details
Cerebrospinal Fluid (CSF)Detected and Quantified3.6 (1.8-5.5) uMNewborn (0-30 days old)BothNormal details
Cerebrospinal Fluid (CSF)Detected and Quantified2.4 (0.6-4.1) uMChildren (1-13 years old)BothNormal details
Cerebrospinal Fluid (CSF)Detected and Quantified1.8 (0.6-5.1) uMAdult (>18 years old)BothNormal details
FecesDetected but not QuantifiedNot QuantifiedAdult (>18 years old)Both
Normal		 details
FecesDetected but not QuantifiedNot QuantifiedNot SpecifiedBoth
Normal		 details
FecesDetected but not QuantifiedNot QuantifiedChildren (6 - 18 years old)Not SpecifiedNormal details
FecesDetected but not QuantifiedNot QuantifiedAdult (>18 years old)Both
Normal		 details
FecesDetected but not QuantifiedNot QuantifiedAdult (>18 years old)Not Specified
Normal		 details
FecesDetected and Quantified1242 nmol/g wet fecesAdult (>18 years old)Not Specified
Normal		 details
FecesDetected and Quantified1540 nmol/g wet fecesAdult (>18 years old)Not Specified
Normal		 details
FecesDetected and Quantified1363 nmol/g wet fecesAdult (>18 years old)Not Specified
Normal		 details
FecesDetected but not QuantifiedNot QuantifiedAdult (>18 years old)FemaleNormal details
FecesDetected but not QuantifiedNot QuantifiedAdult (>18 years old)Both
Normal		 details
FecesDetected but not QuantifiedNot QuantifiedAdult (>18 years old)Both
Normal		 details
FecesDetected but not QuantifiedNot QuantifiedAdult (>18 years old)Both
Normal		 details
FecesDetected but not QuantifiedNot QuantifiedAdult (>18 years old)Both
Normal		 details
SalivaDetected and Quantified3.72 +/- 2.50 uMAdult (>18 years old)FemaleNormal details
SalivaDetected and Quantified5.83 +/- 5.65 uMAdult (>18 years old)Male
Normal
    • Sugimoto et al. (...
 details
SalivaDetected but not QuantifiedNot QuantifiedAdult (>18 years old)BothNormal details
SalivaDetected and Quantified1.55 +/- 0.973 uMAdult (>18 years old)Female
Normal
    • Sugimoto et al. (...
 details
SalivaDetected and Quantified1.57 +/- 1.14 uMAdult (>18 years old)Both
Normal
    • Sugimoto et al. (...
 details
SalivaDetected but not QuantifiedNot QuantifiedAdult (>18 years old)Male
Normal		 details
SalivaDetected but not QuantifiedNot QuantifiedAdult (>18 years old)Male
Normal		 details
SalivaDetected but not QuantifiedNot QuantifiedAdult (>18 years old)Male
Normal		 details
SalivaDetected but not QuantifiedNot QuantifiedAdult (>18 years old)Male
Normal		 details
SalivaDetected but not QuantifiedNot QuantifiedAdult (>18 years old)Male
Normal		 details
SalivaDetected but not QuantifiedNot QuantifiedAdult (>18 years old)Male
Normal		 details
SalivaDetected but not QuantifiedNot QuantifiedAdult (>18 years old)Male
Normal		 details
SalivaDetected but not QuantifiedNot QuantifiedAdult (>18 years old)Male
Normal		 details
SalivaDetected but not QuantifiedNot QuantifiedAdult (>18 years old)Male
Normal		 details
SalivaDetected but not QuantifiedNot QuantifiedAdult (>18 years old)Male
Normal		 details
SalivaDetected and Quantified2.12 +/- 1.17 uMAdult (>18 years old)Both
Normal
    • Sugimoto et al. (...
 details
SalivaDetected and Quantified1.91 +/- 0.37 uMAdult (>18 years old)Both
Normal		 details
SalivaDetected and Quantified2.15 +/- 0.34 uMAdult (>18 years old)Both
Normal		 details
SalivaDetected and Quantified1.11 +/- 0.20 uMAdult (>18 years old)Both
Normal		 details
SalivaDetected and Quantified28.15 +/- 11.95 uMAdult (>18 years old)BothNormal
    • Zerihun T. Dame, ...
 details
UrineDetected and Quantified6.63 +/- 6.938 umol/mmol creatinineChildren (1 - 13 years old)Not Specified
Normal
    • Analysis of 30 no...
 details
UrineDetected and Quantified3.957 +/- 1.470 umol/mmol creatinineAdult (>18 years old)Not SpecifiedNormal details
UrineDetected and Quantified4.67 (2.8-6.38) umol/mmol creatinineAdult (>18 years old)BothNormal
    • Geigy Scientific ...
    • West Cadwell, N.J...
    • Basel, Switzerlan...
 details
UrineDetected and Quantified4-60 umol/mmol creatinineChildren (1 - 18 years old)Both
Normal
    • BC Children's Hos...
 details
UrineDetected and Quantified7.2 (1.8-24.1) umol/mmol creatinineAdult (>18 years old)Both
Normal		 details
UrineDetected but not QuantifiedNot QuantifiedAdult (>18 years old)BothNormal details
UrineDetected and Quantified0-25 umol/mmol creatinineAdult (>18 years old)BothNormal details
UrineDetected and Quantified17.1 +/- 1.0 umol/mmol creatinineChildren (1-13 years old)BothNormal details
UrineDetected and Quantified5.314 +/- 1.583 umol/mmol creatinineAdult (>18 years old)Male
Normal		 details
UrineDetected and Quantified7.2 +/- 3.1 umol/mmol creatinineAdult (>18 years old)BothNormal details
UrineDetected and Quantified5.78 +/- 3.99 umol/mmol creatinineChildren (1-13 years old)BothNormal details
UrineDetected and Quantified4.82 +/- 2.20 umol/mmol creatinineAdolescent (13-18 years old)BothNormal details
UrineDetected and Quantified2.30 +/- 2.48 umol/mmol creatinineAdult (>18 years old)BothNormal details
UrineDetected and Quantified17.09 (10.51-28.19) umol/mmol creatinineNewborn (0-30 days old)Both
Normal
    • Analysis of 40 NI...
 details
UrineDetected and Quantified<5.2 umol/mmol creatinineInfant (0-1 year old)Both
Normal		 details
UrineDetected but not QuantifiedNot QuantifiedAdult (>18 years old)Male
Normal		 details
UrineDetected but not QuantifiedNot QuantifiedAdult (>18 years old)MaleNormal details
Abnormal Concentrations
BiospecimenStatusValueAgeSexConditionReferenceDetails
BloodDetected and Quantified5.7 +/- 0.4 uMAdult (>18 years old)BothLesch-Nyhan syndrome details
BloodDetected and Quantified3.1 uMAdult (>18 years old)FemalePhosphoribosylpyrophosphate Synthetase Superactivity details
BloodDetected and Quantified52.3 uMAdult (>18 years old)BothHeart Transplant details
BloodDetected and Quantified18.88 +/- 8.30 uMAdult (>18 years old)Bothuremia details
BloodDetected and Quantified5.56 +/- 1.74 uMAdult (>18 years old)BothCanavan disease details
BloodDetected and Quantified1.6 uMChildren (1-13 years old)Male
Xanthinuria type 1		 details
BloodDetected and Quantified3.6 uMAdult (>18 years old)Female
Xanthinuria type 1		 details
BloodDetected and Quantified0-31 uMChildren (1-13 years old)BothXanthinuria type 1 details
BloodDetected and Quantified7.0 +/- 3.2 uMAdult (>18 years old)Male
Lesch-Nyhan syndrome		 details
BloodDetected and Quantified14.706 +/- 11.765 uMAdult (>18 years old)Both
Uremia		 details
BloodDetected and Quantified4.8 +/- 1.0 uMAdult (>18 years old)BothSolid tumors details
Cerebrospinal Fluid (CSF)Detected and Quantified5.71 (3.99-7.43) uMAdult (>18 years old)Both
Hydrocephalus		 details
Cerebrospinal Fluid (CSF)Detected and Quantified9.91 (8.01-11.8) uMAdult (>18 years old)Both
Hydrocephalus		 details
Cerebrospinal Fluid (CSF)Detected and Quantified5.2 uMChildren (1 - 13 years old)Not SpecifiedIsolated 3-Methylcrotonyl-CoA Carboxylase Deficiency details
Cerebrospinal Fluid (CSF)Detected and Quantified2.50 (2.00-3.00) uMAdult (>18 years old)BothDegenerative disc disease details
FecesDetected but not QuantifiedNot QuantifiedAdult (>18 years old)BothColorectal Cancer details
FecesDetected but not QuantifiedNot QuantifiedAdult (>18 years old)Femaleankylosing spondylitis details
FecesDetected but not QuantifiedNot QuantifiedAdult (>18 years old)Femalerheumatoid arthritis details
FecesDetected but not QuantifiedNot QuantifiedChildren (6 - 18 years old)Not SpecifiedCrohns disease details
FecesDetected but not QuantifiedNot QuantifiedChildren (6 - 18 years old)Not SpecifiedUlcerative colitis details
FecesDetected but not QuantifiedNot QuantifiedChildren (6 - 18 years old)Not SpecifiedUnclassified IBD details
FecesDetected but not QuantifiedNot QuantifiedAdult (>18 years old)Both
Colorectal cancer		 details
FecesDetected but not QuantifiedNot QuantifiedAdult (>18 years old)Both
Irritable bowel syndrome		 details
FecesDetected but not QuantifiedNot QuantifiedAdult (>18 years old)Both
Colorectal cancer		 details
SalivaDetected but not QuantifiedNot QuantifiedAdult (>18 years old)MaleAttachment loss  details
SalivaDetected but not QuantifiedNot QuantifiedAdult (>18 years old)MalePeriodontal Probing Depth details
SalivaDetected but not QuantifiedNot QuantifiedAdult (>18 years old)BothOral cancer details
SalivaDetected but not QuantifiedNot QuantifiedAdult (>18 years old)FemaleBreast cancer details
SalivaDetected but not QuantifiedNot QuantifiedAdult (>18 years old)Not SpecifiedPancreatic cancer details
SalivaDetected but not QuantifiedNot QuantifiedAdult (>18 years old)Not SpecifiedPeriodontal diseases details
SalivaDetected and Quantified2.60 +/- 1.07 uMAdult (>18 years old)MaleAlzheimer's disease details
SalivaDetected and Quantified2.99 +/- 1.49 uMAdult (>18 years old)MaleFrontotemporal lobe dementia details
SalivaDetected and Quantified3.53 +/- 3.84 uMAdult (>18 years old)BothLewy body disease details
UrineDetected and Quantified9.434 +/- 6.582 umol/mmol creatinineChildren (1 - 13 years old)Not Specified
Eosinophilic esophagitis
    • Analysis of 30 no...
 details
UrineDetected and Quantified16.846 umol/mmol creatinineAdult (>18 years old)FemalePhosphoribosylpyrophosphate Synthetase Superactivity details
UrineDetected and Quantified6.8 +/- 4.8 umol/mmol creatinineNot SpecifiedBothLung cancer details
UrineDetected but not QuantifiedNot QuantifiedAdult (>18 years old)BothBladder cancer details
UrineDetected and Quantified46 umol/mmol creatinineChildren (1-13 years old)Not Specified
Molybdenum cofactor deficiency		 details
UrineDetected and Quantified65 umol/mmol creatinineAdult (>18 years old)Male
Xanthinuria type 1		 details
UrineDetected and Quantified74.846 umol/mmol creatinineAdult (>18 years old)Male
Lesch-Nyhan syndrome		 details
UrineDetected and Quantified88 umol/mmol creatinineNewborn (0-30 days old)Not Specified
Molybdenum cofactor deficiency		 details
UrineDetected and Quantified4.3-53.0 umol/mmol creatinineChildren (1-13 years old)BothSulfite oxidase deficiency details
UrineDetected and Quantified61.8-138.0 umol/mmol creatinineChildren (1-13 years old)BothXanthinuria type 1 details
UrineDetected but not QuantifiedNot QuantifiedAdult (>18 years old)BothAutosomal dominant polycystic kidney disease (ADPKD) details
UrineDetected and Quantified15.12 +/- 17.44 umol/mmol creatinineAdult (>18 years old)BothCanavan disease details
UrineDetected but not QuantifiedNot QuantifiedAdult (>18 years old)Male
Hepatocellular carcinoma 		details
Associated Disorders and Diseases
Disease References
Lesch-Nyhan syndrome
  1. Harkness RA, McCreanor GM, Watts RW: Lesch-Nyhan syndrome and its pathogenesis: purine concentrations in plasma and urine with metabolite profiles in CSF. J Inherit Metab Dis. 1988;11(3):239-52. [PubMed:3148065 ]
  2. Puig JG, Torres RJ, Mateos FA, Ramos TH, Arcas JM, Buno AS, O'Neill P: The spectrum of hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency. Clinical experience based on 22 patients from 18 Spanish families. Medicine (Baltimore). 2001 Mar;80(2):102-12. [PubMed:11307586 ]
Canavan disease
  1. Tavazzi B, Lazzarino G, Leone P, Amorini AM, Bellia F, Janson CG, Di Pietro V, Ceccarelli L, Donzelli S, Francis JS, Giardina B: Simultaneous high performance liquid chromatographic separation of purines, pyrimidines, N-acetylated amino acids, and dicarboxylic acids for the chemical diagnosis of inborn errors of metabolism. Clin Biochem. 2005 Nov;38(11):997-1008. Epub 2005 Sep 1. [PubMed:16139832 ]
Thymidine treatment
  1. Leyva A, Schornagel JH, Kraal I, Wadman SK, Pinedo HM: Clinical and biochemical studies of high-dose thymidine treatment in patients with solid tumors. J Cancer Res Clin Oncol. 1984;107(3):211-6. [PubMed:6736109 ]
Uremia
  1. Duranton F, Cohen G, De Smet R, Rodriguez M, Jankowski J, Vanholder R, Argiles A: Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol. 2012 Jul;23(7):1258-70. doi: 10.1681/ASN.2011121175. Epub 2012 May 24. [PubMed:22626821 ]
  2. Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jorres A, Lemke HD, Massy ZA, Passlick-Deetjen J, Rodriguez M, Stegmayr B, Stenvinkel P, Tetta C, Wanner C, Zidek W: Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 2003 May;63(5):1934-43. doi: 10.1046/j.1523-1755.2003.00924.x. [PubMed:12675874 ]
Xanthinuria type 1
  1. Mateos FA, Puig JG, Jimenez ML, Fox IH: Hereditary xanthinuria. Evidence for enhanced hypoxanthine salvage. J Clin Invest. 1987 Mar;79(3):847-52. [PubMed:3818951 ]
  2. Mraz M, Hurba O, Bartl J, Dolezel Z, Marinaki A, Fairbanks L, Stiburkova B: Modern diagnostic approach to hereditary xanthinuria. Urolithiasis. 2015 Feb;43(1):61-7. doi: 10.1007/s00240-014-0734-4. Epub 2014 Nov 6. [PubMed:25370766 ]
  3. Eggermann T, Spengler S, Denecke B, Zerres K, Mache CJ: Multi-exon deletion in the XDH gene as a cause of classical xanthinuria. Clin Nephrol. 2013 Jan;79(1):78-80. [PubMed:23249873 ]
Degenerative disc disease
  1. Eells JT, Spector R: Purine and pyrimidine base and nucleoside concentrations in human cerebrospinal fluid and plasma. Neurochem Res. 1983 Nov;8(11):1451-7. [PubMed:6656991 ]
Hydrocephalus
  1. Castro-Gago M, Rodriguez IN, Rodriguez-Nunez A, Guitian JP, Rocamonde SL, Rodriguez-Segade S: Therapeutic criteria in hydrocephalic children. Childs Nerv Syst. 1989 Dec;5(6):361-3. [PubMed:2611770 ]
3-Methyl-crotonyl-glycinuria
  1. de Kremer RD, Latini A, Suormala T, Baumgartner ER, Larovere L, Civallero G, Guelbert N, Paschini-Capra A, Depetris-Boldini C, Mayor CQ: Leukodystrophy and CSF purine abnormalities associated with isolated 3-methylcrotonyl-CoA carboxylase deficiency. Metab Brain Dis. 2002 Mar;17(1):13-8. [PubMed:11893004 ]
Irritable bowel syndrome
  1. Ponnusamy K, Choi JN, Kim J, Lee SY, Lee CH: Microbial community and metabolomic comparison of irritable bowel syndrome faeces. J Med Microbiol. 2011 Jun;60(Pt 6):817-27. doi: 10.1099/jmm.0.028126-0. Epub 2011 Feb 17. [PubMed:21330412 ]
Colorectal cancer
  1. Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y. eCollection 2016. [PubMed:27275383 ]
  2. Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016. [PubMed:27015276 ]
  3. Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18. [PubMed:25037050 ]
Crohn's disease
  1. Kolho KL, Pessia A, Jaakkola T, de Vos WM, Velagapudi V: Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease. J Crohns Colitis. 2017 Mar 1;11(3):321-334. doi: 10.1093/ecco-jcc/jjw158. [PubMed:27609529 ]
Ulcerative colitis
  1. Kolho KL, Pessia A, Jaakkola T, de Vos WM, Velagapudi V: Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease. J Crohns Colitis. 2017 Mar 1;11(3):321-334. doi: 10.1093/ecco-jcc/jjw158. [PubMed:27609529 ]
Rheumatoid arthritis
  1. Tie-juan ShaoZhi-xing HeZhi-jun XieHai-chang LiMei-jiao WangCheng-ping Wen. Characterization of ankylosing spondylitis and rheumatoid arthritis using 1H NMR-based metabolomics of human fecal extracts. Metabolomics. April 2016, 12:70 [Link]
Perillyl alcohol administration for cancer treatment
  1. Sugimoto M, Wong DT, Hirayama A, Soga T, Tomita M: Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. Metabolomics. 2010 Mar;6(1):78-95. Epub 2009 Sep 10. [PubMed:20300169 ]
Pancreatic cancer
  1. Sugimoto M, Wong DT, Hirayama A, Soga T, Tomita M: Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. Metabolomics. 2010 Mar;6(1):78-95. Epub 2009 Sep 10. [PubMed:20300169 ]
Periodontal disease
  1. Sugimoto M, Wong DT, Hirayama A, Soga T, Tomita M: Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. Metabolomics. 2010 Mar;6(1):78-95. Epub 2009 Sep 10. [PubMed:20300169 ]
Alzheimer's disease
  1. Tsuruoka M, Hara J, Hirayama A, Sugimoto M, Soga T, Shankle WR, Tomita M: Capillary electrophoresis-mass spectrometry-based metabolome analysis of serum and saliva from neurodegenerative dementia patients. Electrophoresis. 2013 Oct;34(19):2865-72. doi: 10.1002/elps.201300019. Epub 2013 Sep 6. [PubMed:23857558 ]
Frontotemporal dementia
  1. Tsuruoka M, Hara J, Hirayama A, Sugimoto M, Soga T, Shankle WR, Tomita M: Capillary electrophoresis-mass spectrometry-based metabolome analysis of serum and saliva from neurodegenerative dementia patients. Electrophoresis. 2013 Oct;34(19):2865-72. doi: 10.1002/elps.201300019. Epub 2013 Sep 6. [PubMed:23857558 ]
Lewy body disease
  1. Tsuruoka M, Hara J, Hirayama A, Sugimoto M, Soga T, Shankle WR, Tomita M: Capillary electrophoresis-mass spectrometry-based metabolome analysis of serum and saliva from neurodegenerative dementia patients. Electrophoresis. 2013 Oct;34(19):2865-72. doi: 10.1002/elps.201300019. Epub 2013 Sep 6. [PubMed:23857558 ]
Attachment loss
  1. Liebsch C, Pitchika V, Pink C, Samietz S, Kastenmuller G, Artati A, Suhre K, Adamski J, Nauck M, Volzke H, Friedrich N, Kocher T, Holtfreter B, Pietzner M: The Saliva Metabolome in Association to Oral Health Status. J Dent Res. 2019 Jun;98(6):642-651. doi: 10.1177/0022034519842853. Epub 2019 Apr 26. [PubMed:31026179 ]
Periodontal Probing Depth
  1. Liebsch C, Pitchika V, Pink C, Samietz S, Kastenmuller G, Artati A, Suhre K, Adamski J, Nauck M, Volzke H, Friedrich N, Kocher T, Holtfreter B, Pietzner M: The Saliva Metabolome in Association to Oral Health Status. J Dent Res. 2019 Jun;98(6):642-651. doi: 10.1177/0022034519842853. Epub 2019 Apr 26. [PubMed:31026179 ]
Lung Cancer
  1. Wishart DS, Knox C, Guo AC, Eisner R, Young N, Gautam B, Hau DD, Psychogios N, Dong E, Bouatra S, Mandal R, Sinelnikov I, Xia J, Jia L, Cruz JA, Lim E, Sobsey CA, Shrivastava S, Huang P, Liu P, Fang L, Peng J, Fradette R, Cheng D, Tzur D, Clements M, Lewis A, De Souza A, Zuniga A, Dawe M, Xiong Y, Clive D, Greiner R, Nazyrova A, Shaykhutdinov R, Li L, Vogel HJ, Forsythe I: HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res. 2009 Jan;37(Database issue):D603-10. doi: 10.1093/nar/gkn810. Epub 2008 Oct 25. [PubMed:18953024 ]
Autosomal dominant polycystic kidney disease
  1. Gronwald W, Klein MS, Zeltner R, Schulze BD, Reinhold SW, Deutschmann M, Immervoll AK, Boger CA, Banas B, Eckardt KU, Oefner PJ: Detection of autosomal dominant polycystic kidney disease by NMR spectroscopic fingerprinting of urine. Kidney Int. 2011 Jun;79(11):1244-53. doi: 10.1038/ki.2011.30. Epub 2011 Mar 9. [PubMed:21389975 ]
Eosinophilic esophagitis
  1. Slae, M., Huynh, H., Wishart, D.S. (2014). Analysis of 30 normal pediatric urine samples via NMR spectroscopy (unpublished work). NA.
Hepatocellular carcinoma
  1. Wu H, Xue R, Dong L, Liu T, Deng C, Zeng H, Shen X: Metabolomic profiling of human urine in hepatocellular carcinoma patients using gas chromatography/mass spectrometry. Anal Chim Acta. 2009 Aug 19;648(1):98-104. doi: 10.1016/j.aca.2009.06.033. Epub 2009 Jun 21. [PubMed:19616694 ]
Molybdenum cofactor deficiency
  1. van Gennip AH, Abeling NG, Stroomer AE, Overmars H, Bakker HD: The detection of molybdenum cofactor deficiency: clinical symptomatology and urinary metabolite profile. J Inherit Metab Dis. 1994;17(1):142-5. [PubMed:8051926 ]
Sulfite oxidase deficiency, ISOLATED
  1. Rashed MS, Saadallah AA, Rahbeeni Z, Eyaid W, Seidahmed MZ, Al-Shahwan S, Salih MA, Osman ME, Al-Amoudi M, Al-Ahaidib L, Jacob M: Determination of urinary S-sulphocysteine, xanthine and hypoxanthine by liquid chromatography-electrospray tandem mass spectrometry. Biomed Chromatogr. 2005 Apr;19(3):223-30. [PubMed:15558695 ]
Phosphoribosylpyrophosphate Synthetase Superactivity
  1. Garcia-Pavia P, Torres RJ, Rivero M, Ahmed M, Garcia-Puig J, Becker MA: Phosphoribosylpyrophosphate synthetase overactivity as a cause of uric acid overproduction in a young woman. Arthritis Rheum. 2003 Jul;48(7):2036-41. doi: 10.1002/art.11058. [PubMed:12847698 ]
Associated OMIM IDs
DrugBank IDDB04076
Phenol Explorer Compound IDNot Available
FooDB IDFDB003949
KNApSAcK IDC00001502
Chemspider ID768
KEGG Compound IDC00262
BioCyc IDHYPOXANTHINE
BiGG ID34434
Wikipedia LinkHypoxanthine
METLIN ID83
PubChem Compound790
PDB IDNot Available
ChEBI ID17368
Food Biomarker OntologyNot Available
VMH IDHXAN
MarkerDB IDMDB00013421
Good Scents IDNot Available
References
Synthesis Reference Shaw, Elliott.New synthesis of the purines adenine, hypoxanthine, xanthine, and isoguanine. Journal of Biological Chemistry (1950), 185 439-47.
Material Safety Data Sheet (MSDS)Not Available
General References
  1. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009 Feb 12;457(7231):910-4. doi: 10.1038/nature07762. [PubMed:19212411 ]
  2. Eells JT, Spector R: Purine and pyrimidine base and nucleoside concentrations in human cerebrospinal fluid and plasma. Neurochem Res. 1983 Nov;8(11):1451-7. [PubMed:6656991 ]
  3. Ohdoi C, Nyhan WL, Kuhara T: Chemical diagnosis of Lesch-Nyhan syndrome using gas chromatography-mass spectrometry detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Jul 15;792(1):123-30. [PubMed:12829005 ]
  4. Nakayama Y, Kinoshita A, Tomita M: Dynamic simulation of red blood cell metabolism and its application to the analysis of a pathological condition. Theor Biol Med Model. 2005 May 9;2:18. [PubMed:15882454 ]
  5. Bullo B, Marlewski M, Smolenski RT, Rutkowski B, Swierczynski J, Manitius J: Erythrocyte nucleotides and blood hypoxanthine in patients with uremia evaluated immediately and 24 hours after hemodialysis. Ren Fail. 1996 Mar;18(2):247-52. [PubMed:8723362 ]
  6. Ihara H, Shino Y, Morita Y, Kawaguchi E, Hashizume N, Yoshida M: Is skeletal muscle damaged by the oxidative stress following anaerobic exercise? J Clin Lab Anal. 2001;15(5):239-43. [PubMed:11574951 ]
  7. Inokuchi T, Moriwaki Y, Takahashi S, Tsutsumi Z, Ka T, Yamamoto A, Cheng J, Hashimoto-Tamaoki T, Hada T, Yamamoto T: Identification of a new point mutation in hypoxanthine phosphoribosyl transferase responsible for hyperuricemia in a female patient. Metabolism. 2004 Nov;53(11):1500-2. [PubMed:15536609 ]
  8. Niklasson F: Simultaneous liquid-chromatographic determination of hypoxanthine, xanthine, urate, and creatinine in cerebrospinal fluid, with direct injection. Clin Chem. 1983 Aug;29(8):1543-6. [PubMed:6872216 ]
  9. Pietz J, Guttenberg N, Gluck L: Hypoxanthine: a marker for asphyxia. Obstet Gynecol. 1988 Nov;72(5):762-6. [PubMed:3140152 ]
  10. Saari H: Oxygen derived free radicals and synovial fluid hyaluronate. Ann Rheum Dis. 1991 Jun;50(6):389-92. [PubMed:1711835 ]
  11. Castro-Gago M, Rodriguez IN, Rodriguez-Nunez A, Guitian JP, Rocamonde SL, Rodriguez-Segade S: Therapeutic criteria in hydrocephalic children. Childs Nerv Syst. 1989 Dec;5(6):361-3. [PubMed:2611770 ]
  12. Storm H, Rognum TO, Saugstad OD, Skullerud K, Reichelt KL: Beta-endorphin immunoreactivity in spinal fluid and hypoxanthine in vitreous humour related to brain stem gliosis in sudden infant death victims. Eur J Pediatr. 1994 Sep;153(9):675-81. [PubMed:7957429 ]
  13. Koellner G, Luic M, Shugar D, Saenger W, Bzowska A: Crystal structure of calf spleen purine nucleoside phosphorylase in a complex with hypoxanthine at 2.15 A resolution. J Mol Biol. 1997 Jan 17;265(2):202-16. [PubMed:9020983 ]
  14. Kaya M, Moriwaki Y, Ka T, Inokuchi T, Yamamoto A, Takahashi S, Tsutsumi Z, Tsuzita J, Oku Y, Yamamoto T: Plasma concentrations and urinary excretion of purine bases (uric acid, hypoxanthine, and xanthine) and oxypurinol after rigorous exercise. Metabolism. 2006 Jan;55(1):103-7. [PubMed:16324927 ]
  15. Smolenska Z, Kaznowska Z, Zarowny D, Simmonds HA, Smolenski RT: Effect of methotrexate on blood purine and pyrimidine levels in patients with rheumatoid arthritis. Rheumatology (Oxford). 1999 Oct;38(10):997-1002. [PubMed:10534552 ]
  16. Saiki S, Sato T, Kohzuki M, Kamimoto M, Yosida T: Changes in serum hypoxanthine levels by exercise in obese subjects. Metabolism. 2001 Jun;50(6):627-30. [PubMed:11398135 ]
  17. Gudbjornsson B, Zak A, Niklasson F, Hallgren R: Hypoxanthine, xanthine, and urate in synovial fluid from patients with inflammatory arthritides. Ann Rheum Dis. 1991 Oct;50(10):669-72. [PubMed:1958086 ]
  18. Saiki S, Sato T, Hiwatari M, Harada T, Oouchi M, Kamimoto M: Relation between changes in serum hypoxanthine levels by exercise and daily physical activity in the elderly. Tohoku J Exp Med. 1999 May;188(1):71-4. [PubMed:10494902 ]
  19. Duranton F, Cohen G, De Smet R, Rodriguez M, Jankowski J, Vanholder R, Argiles A: Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol. 2012 Jul;23(7):1258-70. doi: 10.1681/ASN.2011121175. Epub 2012 May 24. [PubMed:22626821 ]
  20. Elshenawy S, Pinney SE, Stuart T, Doulias PT, Zura G, Parry S, Elovitz MA, Bennett MJ, Bansal A, Strauss JF 3rd, Ischiropoulos H, Simmons RA: The Metabolomic Signature of the Placenta in Spontaneous Preterm Birth. Int J Mol Sci. 2020 Feb 4;21(3). pii: ijms21031043. doi: 10.3390/ijms21031043. [PubMed:32033212 ]

Enzymes

Enzyme Details
1. Xanthine dehydrogenase/oxidase
General function:
Involved in oxidoreductase activity
Specific function:
Key enzyme in purine degradation. Catalyzes the oxidation of hypoxanthine to xanthine. Catalyzes the oxidation of xanthine to uric acid. Contributes to the generation of reactive oxygen species. Has also low oxidase activity towards aldehydes (in vitro).
Gene Name:
XDH
Uniprot ID:
P47989
Molecular weight:
146422.99
Reactions
Hypoxanthine + NAD + Water → Xanthine + NADHdetails
Hypoxanthine + NAD + Water → Xanthine + NADH + Hydrogen Iondetails
Hypoxanthine + Oxygen + Water → Xanthine + Hydrogen peroxidedetails
Enzyme Details
2. Hypoxanthine-guanine phosphoribosyltransferase
General function:
Involved in hypoxanthine phosphoribosyltransferase activity
Specific function:
Converts guanine to guanosine monophosphate, and hypoxanthine to inosine monophosphate. Transfers the 5-phosphoribosyl group from 5-phosphoribosylpyrophosphate onto the purine. Plays a central role in the generation of purine nucleotides through the purine salvage pathway.
Gene Name:
HPRT1
Uniprot ID:
P00492
Molecular weight:
24579.155
Reactions
Inosinic acid + Pyrophosphate → Hypoxanthine + Phosphoribosyl pyrophosphatedetails
Enzyme Details
3. Equilibrative nucleoside transporter 2
General function:
Involved in nucleoside transmembrane transporter activity
Specific function:
Mediates equilibrative transport of purine, pyrimidine nucleosides and the purine base hypoxanthine. Less sensitive than SLC29A1 to inhibition by nitrobenzylthioinosine (NBMPR), dipyridamole, dilazep and draflazine
Gene Name:
SLC29A2
Uniprot ID:
Q14542
Molecular weight:
50112.3
Enzyme Details
4. Purine nucleoside phosphorylase
General function:
Involved in purine-nucleoside phosphorylase activity
Specific function:
The purine nucleoside phosphorylases catalyze the phosphorolytic breakdown of the N-glycosidic bond in the beta-(deoxy)ribonucleoside molecules, with the formation of the corresponding free purine bases and pentose-1-phosphate.
Gene Name:
PNP
Uniprot ID:
P00491
Molecular weight:
32117.69
Reactions
Inosine + Phosphate → Hypoxanthine + Ribose 1-phosphatedetails
Deoxyinosine + Phosphate → Hypoxanthine + Deoxyribose 1-phosphatedetails
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]